Abstract
The U.S. Food and Drug Administration (FDA) approved Leqembi (lecanemab‐irmb) via its accelerated approval pathway for the treatment of Alzheimer's disease, the agency announced in a news release on Jan. 6. Leqembi is the second of a new category of medications approved for Alzheimer's disease that target the fundamental pathophysiology of the disease. These medications represent an important advancement in the ongoing fight to effectively treat Alzheimer's disease.
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献